Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer
PURPOSEAbiraterone acetate (AA) is approved for prostate cancer at a standard dose of 1,000 mg fasting. Because of a significant food effect, a lower dose (250 mg with food—AA low dose [AALD]) shows similar efficacy at 75% lower cost. In Brazil, 80% of patients rely on the public health care system,...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Clinical Oncology
2025-08-01
|
| Seri Bilgileri: | JCO Global Oncology |
| Online Erişim: | https://ascopubs.org/doi/10.1200/GO-25-00132 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|